Arch Therapeutics ARTH Stock
Arch Therapeutics Price Chart
Arch Therapeutics ARTH Financial and Trading Overview
| Arch Therapeutics stock price | 0.0001 USD |
| Previous Close | 3.1 USD |
| Open | 3.14 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 3.14 - 3.25 USD |
| 52 Week Range | 2.02 - 12 USD |
| Volume | 224 USD |
| Avg. Volume | 874 USD |
| Market Cap | 4.18M USD |
| Beta (5Y Monthly) | 0.744194 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.01 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 600 USD |
ARTH Valuation Measures
| Enterprise Value | 8.68M USD |
| Trailing P/E | N/A |
| Forward P/E | 0.22460262 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 135.87938 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 282.528 |
| Enterprise Value/EBITDA | -1.687 |
Trading Information
Arch Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.744194 |
| 52-Week Change | -69.22% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 12 USD |
| 52 Week Low | 2.02 USD |
| 50-Day Moving Average | 3.02 USD |
| 200-Day Moving Average | 5.21 USD |
ARTH Share Statistics
| Avg. Volume (3 month) | 874 USD |
| Avg. Daily Volume (10-Days) | 710 USD |
| Shares Outstanding | 1.29M |
| Float | 1.06M |
| Short Ratio | N/A |
| % Held by Insiders | 14.43% |
| % Held by Institutions | 0.0060% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:200 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | September 30, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | September 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -16751.29% |
| Gross Margin | -74.42% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -212.28% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 30.74K USD |
| Revenue Per Share (ttm) | 0.03 USD |
| Quarterly Revenue Growth (yoy) | 432.09% |
| Gross Profit (ttm) | -35837 USD |
| EBITDA | -5146708 USD |
| Net Income Avi to Common (ttm) | -5637922 USD |
| Diluted EPS (ttm) | -4.1 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 29.5K USD |
| Total Cash Per Share (mrq) | 0.02 USD |
| Total Debt (mrq) | 4.67M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.199 |
| Book Value Per Share (mrq) | -5.01 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -3493772 USD |
| Levered Free Cash Flow (ttm) | -1311697 USD |
Profile of Arch Therapeutics
| Country | United States |
| State | MA |
| City | Framingham |
| Address | 235 Walnut Street |
| ZIP | 01702 |
| Phone | 617 431 2313 |
| Website | https://www.archtherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 8 |
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.
Q&A For Arch Therapeutics Stock
What is a current ARTH stock price?
Arch Therapeutics ARTH stock price today per share is 0.0001 USD.
How to purchase Arch Therapeutics stock?
You can buy ARTH shares on the OTC Markets EXMKT exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Arch Therapeutics?
The stock symbol or ticker of Arch Therapeutics is ARTH.
Which industry does the Arch Therapeutics company belong to?
The Arch Therapeutics industry is Biotechnology.
How many shares does Arch Therapeutics have in circulation?
The max supply of Arch Therapeutics shares is 4.44M.
What is Arch Therapeutics Price to Earnings Ratio (PE Ratio)?
Arch Therapeutics PE Ratio is now.
What was Arch Therapeutics earnings per share over the trailing 12 months (TTM)?
Arch Therapeutics EPS is -1.01 USD over the trailing 12 months.
Which sector does the Arch Therapeutics company belong to?
The Arch Therapeutics sector is Healthcare.